Systemic therapy in advanced hepatocellular carcinoma.

Clin Mol Hepatol · 2023 · PMC10121316 · PMID 36800697

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In the phase III COSMIC-312 trial, combination of atezolizumab with cabozantinib significantly improved progression-free survival compared to sorafenib (HR 0.63, 95% CI 0.44–0.91), while it did not reach statistical significance for overall survival (HR 0.90, 95% CI 0.69–1.18) [ 21 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.